Genetic Clopidogrel response testing to finetune the antithrombotic regimen in (D)OAC Treated patients undergoing PCI

Not yet recruiting

• Conditions: coronary sclerosis; 10011082

• Registration Number: NL-OMON52157
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2024-04-15

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 520

Inclusion Criteria

• Patients >= 18 years of age
• Patients indicated for indefinite (D)OAC
• Patients undergoing successful PCI for stable or unstable (ACS) coronary
artery disease
• Patients with written informed consent as approved by the ethics committee

Exclusion Criteria

• Contraindication to aspirin • Contraindication to ticagrelor or clopidogrel •
Under the age of 18 years • Planned cardiac surgery • Life expectancy < 1
year • Unable or unwilling to provide informed consent • Pregnancy • Suboptimal
result of stenting as defined by the operator • Need for continued triple
antithrombotic therapy per treating physician • Any other condition putting
patient at excessive risk for bleeding with ticagrelor • Use of gp2b3a
inhibitor • Treatment with a strong CYP3A4 inhibitor or inducer • History of
definite stent thrombosis

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified